Latest Conference Articles

November 8th 2021, 8:37pm

PER® New York Lung Cancer Symposium

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

November 8th 2021, 8:26pm

PER® New York Lung Cancer Symposium

The era of direct inhibitors to treat KRAS G12C-mutated non-small cell lung cancer has arrived in the clinic.

November 7th 2021, 2:00pm

PER® Chemotherapy Foundation Symposium (CFS)

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

November 6th 2021, 8:32pm

PER® New York Lung Cancer Symposium

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

November 6th 2021, 8:28pm

PER® New York Lung Cancer Symposium

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

November 6th 2021, 8:03pm

PER® New York Lung Cancer Symposium

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

November 6th 2021, 2:00pm

PER® New York Lung Cancer Symposium

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

November 6th 2021, 2:00pm

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

November 5th 2021, 8:55pm

PER® New York Lung Cancer Symposium

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

November 5th 2021, 8:55pm

PER® New York Lung Cancer Symposium

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

November 5th 2021, 8:51pm

PER® New York Lung Cancer Symposium

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

November 5th 2021, 7:36pm

PER® Chemotherapy Foundation Symposium (CFS)

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

November 5th 2021, 7:03pm

PER® Chemotherapy Foundation Symposium (CFS)

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

November 5th 2021, 5:00pm

PER® New York Lung Cancer Symposium

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

November 5th 2021, 2:00pm

PER® New York Lung Cancer Symposium

Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.

November 4th 2021, 10:16pm

PER® Chemotherapy Foundation Symposium (CFS)

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

November 4th 2021, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.

November 4th 2021, 9:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.

November 4th 2021, 7:42pm

PER® Chemotherapy Foundation Symposium (CFS)

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

November 4th 2021, 7:14pm

PER® Chemotherapy Foundation Symposium (CFS)

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.